News
Insights
Jobs
Career Advice
Companies
Hotbeds
More

SUBSCRIBE

SUBSCRIBE

News
Insights
Jobs
Career Advice
Companies
Hotbeds
More

Search Query

Search Results

Looking for jobs? Search jobs

2,339 Results

Type

Article (313)
Company Profile (1)
Press Release (2025)

Section

Business (749)
Career Advice (8)
Deals (136)
Drug Development (275)
Employer Resources (1)
FDA (60)
Job Trends (85)
News (1141)
Policy (87)

Tag

Date

Last 7 days (9)
Last 30 days (14)
Last 365 days (107)
2025 (11)
2024 (106)
2023 (111)
2022 (142)
2021 (180)
2020 (170)
2019 (208)
2018 (141)
2017 (142)
2016 (139)
2015 (147)
2014 (114)
2013 (129)
2012 (103)
2011 (107)
2010 (71)

Location

Africa (7)
Asia (86)
Australia (8)
California (2)
Canada (2)
Colorado (1)
Delaware (1)
Europe (180)
Indiana (1)
Maryland (1)
Massachusetts (27)
Minnesota (1)
Nebraska (2)
New Jersey (5)
New York (1)
Northern California (2)
Ohio (1)
Pennsylvania (9)
South America (8)
Texas (1)

Filters

Type

Article (313)
Company Profile (1)
Press Release (2025)

Section

Business (749)
Career Advice (8)
Deals (136)
Drug Development (275)
Employer Resources (1)
FDA (60)
Job Trends (85)
News (1141)
Policy (87)

Tag

Date

Last 7 days (9)
Last 30 days (14)
Last 365 days (107)
2025 (11)
2024 (106)
2023 (111)
2022 (142)
2021 (180)
2020 (170)
2019 (208)
2018 (141)
2017 (142)
2016 (139)
2015 (147)
2014 (114)
2013 (129)
2012 (103)
2011 (107)
2010 (71)

Location

Africa (7)
Asia (86)
Australia (8)
California (2)
Canada (2)
Colorado (1)
Delaware (1)
Europe (180)
Indiana (1)
Maryland (1)
Massachusetts (27)
Minnesota (1)
Nebraska (2)
New Jersey (5)
New York (1)
Northern California (2)
Ohio (1)
Pennsylvania (9)
South America (8)
Texas (1)

2,339 Results for "sage bionetworks".

Sort By

Neuroscience

Biogen Submits Offer to Buy Embattled Partner Sage

Biogen’s proposed acquisition comes after two difficult years of regulatory and clinical challenges, during which shares of Sage Therapeutics have fallen by more than 90%.

January 13, 2025
·
3 min read
·
Heather McKenzie
Business

Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More

J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference. Meanwhile, Biogen proposes to acquire struggling neuro partner Sage, and obesity dominates discussions as Pfizer goes “all in.”

January 15, 2025
·
1 min read
·
Heather McKenzie
Editorial

Embattled Sage Dealt Deeper Blow With Huntington’s Failure

Sage Therapeutics discontinued development of its lead candidate dalzanemdor after a third clinical failure, leading analysts to question the biotech’s future profitability.

November 25, 2024
·
4 min read
·
Heather McKenzie
Huntington’s disease

Sage Scraps Huntington’s Hopeful After Disappointing Phase II Data

After previously failing studies in Parkinson’s and Alzheimer’s, dalzanemdor’s latest stumble in Huntington’s disease has pushed Sage Therapeutics to pull the plug on the NMDA receptor modulator.

November 20, 2024
·
2 min read
·
Tristan Manalac
Podcast

Trodelvy’s Bladder Cancer Withdrawal, Sage Therapeutics Layoffs, Sanofi’s Radiopharma Investment, More

Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million in radiopharma while selling its consumer health unit; Novo Nordisk’s positive Rybelsus results in cardiovascular disease; and more.

October 23, 2024
·
1 min read
·
Heather McKenzie
Earnings

Sage Touts Q3 Zurzuvae Revenue Growth, Will Not Seek MDD Indication

On its third-quarter earnings call Tuesday, Sage highlighted the launch of its Biogen-partnered postpartum depression drug Zurzuvae but said it will stop pursuing approval for major depressive disorder, which the FDA previously denied.

October 30, 2024
·
2 min read
·
Heather McKenzie
Layoffs

Sage Therapeutics Will Lay Off 33% of Employees, Including Over Half of R&D

As part of a strategic reorganization intended in part to support the ongoing launch of its postpartum depression drug, Sage Therapeutics is cutting more than 165 employees.

October 17, 2024
·
2 min read
·
Angela Gabriel
Alzheimer’s disease

Sage Suffers Third Neuro Stumble in Six Months With Disappointing Mid-Stage Alzheimer’s Readout

Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington’s is ongoing, with early data expected later this year.

October 8, 2024
·
2 min read
·
Tristan Manalac
Press Releases

Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen

January 13, 2025
·
1 min read
Clinical research

Biogen, Sage Scrap Essential Tremor Study After Phase II Failure

Biogen and Sage Therapeutics’ investigational neuroactive steroid did not significantly improve upper limb tremors in patients with essential tremor, the companies announced Wednesday.

July 24, 2024
·
2 min read
·
Tristan Manalac

1 of 234

BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.

Explore
About
More

© 1985 - 2025 BioSpace.com. All rights reserved.

twitter
instagram
facebook
linkedin